Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06990711 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
A Phase 1 study of Antibody Mediated Rejection of Lung Transplant, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06990711 is a Phase 1 study of Antibody Mediated Rejection of Lung Transplant that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06990711, a Phase 1 study of Antibody Mediated Rejection of Lung Transplant, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens. We are testing the safety and tolerability of the addition of a novel immunosuppressive medication to routine treatment for antibody-mediated rejection. Future studies will be needed to assess efficacy if this study demonstrates safety
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Siltuximab
Study Locations (2)
Missouri
- Washington University School, of Medicine, Barnes-Jewish Hospital - St Louis
Utah
- University of Utah - Saint Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06990711
The ClinicalTrials.gov registry entry for NCT06990711 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Antibody Mediated Rejection of Lung Transplant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06990711 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, Utah.
Frequently Asked Questions
What is clinical trial NCT06990711 about?
NCT06990711 is a clinical study titled "A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation". Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens. We are testing the safety and tolerability of the addition of a novel immunosuppressive medication to routine treatment for antibody-mediated rejection. Fu...
What is the current status of trial NCT06990711?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-06. Estimated completion is 2028-06-30.
What conditions does trial NCT06990711 study?
This clinical trial studies the following conditions: Antibody Mediated Rejection of Lung Transplant.
What interventions are being tested in trial NCT06990711?
The interventions under investigation include: Placebo (DRUG), Siltuximab (DRUG).
Who is sponsoring clinical trial NCT06990711?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06990711 being conducted?
This trial has 2 study locations across Missouri, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.